menu
    • menu
    [{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Feinstein Institutes \/ Not Applicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Feinstein Institutes \/ Not Applicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Feinstein Institutes \/ Not Applicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Famotidine","moa":"PLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Feinstein Institutes \/ Not Applicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Famotidine","moa":"H2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Feinstein Institutes \/ Not Applicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Feinstein Institutes \/ Feinstein Institutes","highestDevelopmentStatusID":"10","companyTruncated":"Feinstein Institutes \/ Feinstein Institutes"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Feinstein Institutes \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Feinstein Institutes

    Menu

    Feinstein Institutes

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Feinstein Institutes Researcher Discovers Potential Therapeutic Target for Lethal Sepsis

                            Details : The research explores the identification of mAbs working against a pro-inflammatory protein mediator, pCTS-L. These anti-pCTS-L monoclonal antibodies may provide effective therapies for the clinical treatment of human sepsis and other infectious diseases...

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 03, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Litifilimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : Biogen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Experimental Lupus Therapy Shows Promise In Feinstein-led Trial

                            Details : The results from this trial show that BIIB059 (litifilimab) may effectively block the body’s production of harmful inflammatory molecules in people with SLE, easing their joint pain and improving overall disease activity.

                            Product Name : BIIB059

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 15, 2022

                            Lead Product(s) : Litifilimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : Biogen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Famotidine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19, New Study Shows

                            Details : The preclinical study published that Pepcid (famotidine), a histamine 2 receptor (H2R) antagonist, prevents cytokine storm in mice, famotidine did this indirectly because it stimulated signals caused by vagus nerve, a major nerve into the body’s organs...

                            Product Name : Pepcid

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 19, 2022

                            Lead Product(s) : Famotidine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Famotidine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Famotidine Cinical Trial Shows Reduction in Covid-19 Symptoms

                            Details : Famotidine is a safe, low-cost, over-the-counter drug usually used to treat heartburn. People with Covid-19 often get sick because the body’s inflammatory response to the virus gets overactivated.

                            Product Name : Pepcid

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 09, 2022

                            Lead Product(s) : Famotidine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zuranolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Investigational Pill for Postpartum Depression Shows Promise in Clinical Trial Led by the Feinstein Institutes

                            Details : The findings published in the JAMA Psychiatry showed that after two weeks of daily treatment, women treated with zuranolone had a statistically significant reduction in their core symptoms of depression compared to women who received a placebo.

                            Product Name : SAGE-217

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 30, 2021

                            Lead Product(s) : Zuranolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexamethasone,Tocilizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Feinstein Institutes Researchers Find Effective COVID-19 ‘Cytokine Storm’ Treatment

                            Details : Results from the study showed that the most effective treatment was the combination of corticosteroids-such as dexamethasone – with tocilizumab when compared to standard of care.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 20, 2020

                            Lead Product(s) : Dexamethasone,Tocilizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Feinstein Institutes

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remdesivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials

                            Details : The three Feinstein Institutes trials are offered to patients already admitted to Northwell Health hospitals with moderate to severe COVID-19.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 20, 2020

                            Lead Product(s) : Remdesivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth